Zacks Research Analysts Lower Earnings Estimates for Repligen Co. (NASDAQ:RGEN)

Repligen Co. (NASDAQ:RGEN – Free Report) – Research analysts at Zacks Research decreased their Q3 2024 earnings per share (EPS) estimates for Repligen in a research report issued on Wednesday, March 13th. Zacks Research analyst S. Ganoria now anticipates that the biotechnology company will earn $0.38 per share for the quarter, down from their prior […]

Leave a Reply

Your email address will not be published.

Previous post Q3 2024 EPS Estimates for AngioDynamics, Inc. Reduced by Zacks Research (NASDAQ:ANGO)
Next post Zacks Research Analysts Increase Earnings Estimates for United Therapeutics Co. (NASDAQ:UTHR)